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PURPOSE. Stargardt disease (STGD1) is an autosomal recessive retinopathy, caused by
mutations in the retina-specific ATP-binding cassette transporter (ABCA4) gene. To establish
the mutational spectrum and to assess effects of selected deep intronic and common genetic
variants on disease, we performed a comprehensive sequence analysis in a large cohort of
German STGD1 patients.
METHODS. DNA samples of 335 STGD1 patients were analyzed for ABCA4 mutations in its 50
coding exons and adjacent intronic sequences by resequencing array technology or next
generation sequencing (NGS). Parts of intron 30 and 36 were screened by Sanger chain-
terminating dideoxynucleotide sequencing. An in vitro splicing assay was used to test
selected variants for their splicing behavior. By logistic regression analysis we assessed the
association of common ABCA4 alleles while a multivariate logistic regression model
calculated a genetic risk score (GRS).
RESULTS. Our analysis identified 148 pathogenic or likely pathogenic mutations, of which 48
constitute so far unpublished ABCA4-associated disease alleles. Four rare deep intronic
variants were found once in 472 alleles analyzed. In addition, we identified six risk-modulating
common variants. Genetic risk score estimates suggest that defined common ABCA4 variants
influence disease risk in carriers of a single pathogenic ABCA4 allele.
CONCLUSIONS. Our study adds to the mutational spectrum of the ABCA4 gene. Moreover, in our
cohort, deep intronic variants in intron 30 and 36 likely play no or only a minor role in disease
pathology. Of note, our findings demonstrate a possible modifying effect of common
sequence variants on ABCA4-associated disease.
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Stargardt disease (STGD1; Mendelian Inheritance in Man[MIM] 248200) is the leading cause of Mendelian macular
dystrophy that often manifests in the first two decades, but may
also become symptomatic only later in life. It is typically
characterized by bilateral progressive loss of central vision,
color vision defects, and photophobia. The fundus often
presents with yellow-white autofluorescent flecks (fundus
flavimaculatus) and chorioretinal atrophy in the macula,
typically with an initial foveal sparing and variable extension
into the periphery.1,2
Autosomal recessive STGD1 is caused by mutations in the
ABCA4 gene.3 Other retinal phenotypes, such as retinitis
pigmentosa and cone–rod dystrophy, have also been linked to
recessive mutations in this gene.4,5 ABCA4 encodes a member
of the ATP-binding cassette (ABC) superfamily of transmem-
brane proteins specifically localized at the rims and incisures of
outer segment discs of rod and cone photoreceptors.6 In the
retina, ABCA4 transports N-retinylidene-phosphatidylethanol-
amine from the lumen to the cytoplasmic leaflet of photore-
ceptor disc membranes, a process that together with chemical
isomerization facilitates the removal of potentially toxic
retinoid compounds.7 Conversely, impaired ABCA4 function
results in an accumulation of bisretinoids such as A2E in the
RPE. This debris, also known as lipofuscin, is thought to disturb
RPE metabolism and ultimately may cause cell death.8 Current
genotype–phenotype models correlate the degree of residual
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ABCA4 activity with the severity of the retinal disease
phenotype.5,9 In addition, toxic gain-of-function mutations
were described in the ABCA4 gene and were proposed to
contribute to disease severity.10
To date, more than 900 different mutations including
missense, splicing, truncating, and frameshift alterations have
been reported in the ABCA4 gene and shown to be associated
with retinal degeneration (HGMD database, build 2015.4)
(Qiagen, Hilden, Germany). Of these, 72% were identified in
STGD1 patients. Additionally, 1120 rare nonsynonymous
variants (frequency  0.005) were found in coding regions
or highly conserved exon-flanking intronic sequences of the
ABCA4 gene by the Exome Aggregation Consortium (ExAC)
(Cambridge, MA, USA; http://exac.broadinstitute.org; January
2016; in the public domain). These variants encompass 257
known and 863 potential novel disease-associated mutations.
ABCA4 mutations are scattered across all 50 coding exons of
the gene, although representative studies from different
geographic regions reveal the existence of ethnic founder
mutations.9,11–17
Despite detection rates of ABCA4 mutations greatly
increasing over recent years by state-of-the-art analytical
approaches such as next generation sequencing, homozygous
or compound heterozygous mutations are regularly detected in
no more than 70% of STGD1 patients, while a significant
number of patients carry only a single ABCA4 mutation (17–
30%).15,17–21 It has been debated whether some of the carriers
of monoallelic ABCA4 mutations could be combined into a
subgroup of late-onset STGD1 or may present as age-related
macular degeneration (AMD).22,23 Recently, several deep
intronic variants in the ABCA4 gene were reported to
segregate with disease and in some cases to affect correct
splicing. It was suggested that these variants represent a novel
and as yet rather unexplored type of pathogenic ABCA4
mutations.20,21,24–26
To further explore the genetic architecture of ABCA4
pathology in STGD1, we analyzed the ABCA4 gene in a large
German cohort of 335 STGD1 patients referred to our
molecular diagnostics unit at the Institute of Human Genetics,
Regensburg, between 2008 and 2015. The molecular analysis
included sequencing of the 50 coding exons/conserved splice
sites of the ABCA4 gene as well as two regions in intron 30 and
36 reported earlier to harbor deep intronic disease-associated
variants. Moreover, functional studies were performed to assess
pathogenicity of selected ABCA4 variants. Finally, a multivar-
iate logistic regression model was used to investigate the role
of common ABCA4 variants with allele frequencies > 0.01.
MATERIALS AND METHODS
Patients
Sequence analysis included a total of 335 patients (191 female,
144 male) with definite or suspected clinical diagnosis of
STGD1 who underwent routine genetic testing at the Institute
of Human Genetics Regensburg. Referrals between 2008 and
2015 were included in the study. A positive family history of
STGD1 was reported for 35 cases; 131 individuals had a
negative family history, and no further information on the
familial status of retinal degeneration was available for 169
patients. Information on ethnicity was mainly provided by the
patients themselves or was estimated from their first or last
name. A total of 283 patients were Caucasian (80%), 30
patients were from the Middle East, 1 patient was from Asia,
and for 21 patients ethnicity could not unanimously be
determined. A control group of 779 probands free of retinal
disease was recruited from the Lower Franconian region in
Germany27 and used to assess the role of common variants in
STGD1 pathology. In accordance with the German Genetic
Diagnostics Act, written informed consent was obtained from
all subjects. This study adhered to the tenets of the Declaration
of Helsinki.
Molecular Analysis
For DNA extractions, EDTA peripheral blood samples were
obtained from all patients. Mutational analyses of the coding
exons and the flanking intronic sequences [12 bp/þ6 bp
covering the key donor ((CjA) A G G T (AjG) A G T) and
acceptor (Y10 N (CjT) A G (GjA)) splice signals at the exon–
intron boundaries28] of the ABCA4 gene (NM_00350.2) were
mainly performed (186 patients) by a custom-designed
GeneChip CustomSeq Resequencing Array (RetChip) (Affyme-
trix, Santa Clara, CA, USA). Multiplex-PCR products were
amplified by exon flanking oligonucleotide primer pairs
(oligonucleotide sequences will be provided upon request).
The data were analyzed with the Affymetrix GeneChip Analysis
Software (GSEQ) and the SeqC module (JSI medical systems,
Kippenheim, Germany) as previously described.29 For 149
patients, mutation testing was performed by next generation
sequencing (NGS) on an ION Torrent semiconductor personal
sequencing machine (Life Technologies, Darmstadt, Germany)
upon multiplex-PCR amplification of the fragments with the
STARGARDT MASTR kit (Multiplicom, Niel, Belgium). Regions
with a depth of sequence coverage below 303were reanalyzed
by Sanger chain-terminating dideoxynucleotide sequencing on
an ABI 3130xl instrument (Applied Biosystems, Carlsbad, CA,
USA). Next generation sequencing data were analyzed within
the CLC Genomics Workbench (CLC bio, Aarhus, Denmark).
Potentially disease-relevant variants identified by RetChip or
NGS were routinely confirmed by Sanger sequencing. To test
for deep intronic sequence variants in 236 patients, primer
pairs ABCA4-Exon30.1 fwd (50-TCT GAA GTT CCC ACA TAG
TAC TTC C-30)/rev (50-GAT TGT GTT TGA GTG GCT AGG G-30)
and ABCA4-Exon36.1 fwd (50-ACT ACC ACC TTC CTG ACA
ACC AA-30)/rev (50-CTA CAT CTC TCT CCA TAG GCT CAG A-
30) were used to amplify and sequence a 607- and 535-bp
fragment within ABCA4 intervening sequences 30 and 36,
respectively.
Disease-related variants were submitted to the ClinVar
database (Acc. Nos. SCV000281879–SCV000281965, http://
www.ncbi.nlm.nih.gov/clinvar/; in the public domain). All
variants are described according to current nomenclature
guidelines (http://www.hgvs.org/mutnomen; in the public
domain).
Bioinformatic Analyses and Variant Classification
Variants were classified as recommended by the American
College of Medical Genetics and Genomics (ACMG) standards
and guidelines and the Association for Molecular Pathology
(AMP) Clinical Practice Guidelines and Reports without
discrimination between benign or likely benign and were
based on population data, computational data, previous
publications, and functional data. Variant frequency in non-
Finnish Europeans was taken from the browser of the Exome
Aggregation Consortium (ExAC). A variant was classified as
benign if the minor allele frequency (MAF) was ‡0.005 except
for variant c.2588G>C. Variants with MAF below 0.005 or with
an unknown frequency were further tested for disease
relevance by prediction algorithms of the programs Muta-
tionTaster (Mutation Taster, http://www.mutationtaster.org/; in
the public domain) and PolyPhen-2 (PolyPhen2, http://
genetics.bwh.harvard.edu/pph/; in the public domain). A
sequence variant was classified as a variant of uncertain
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significance (vus) when none or only one of the two programs
predicted a possible pathogenic effect. Exceptions to this rule
included missense mutations well documented in the literature
to be disease associated in STGD1 patients. Such variants were
nonetheless classified as ‘‘likely pathogenic.’’ When both
programs, MutationTaster and PolyPhen-2, predicted a patho-
genic effect, the variants were classified as ‘‘likely pathogenic.’’
Stop and frameshift mutations as well as variants with
experimental evidence of ABCA4 dysfunction were classified
as pathogenic. In addition, rare variants were further analyzed
for a potential effect on correct splicing by using the interface
provided by the software package Alamut (Interactive Biosoft-
ware, Rouen, France; Alamut Visual 2.7.1), which combines
five algorithms (SpliceSiteFinder, MaxEntScan, NNSPLICE,
GeneSplicer, and Human Splicing Finder). All tools provide
prediction scores for the normal and the mutant allele. Variants
were selected for further testing by in vitro minigene splicing
assays when the score differences calculated by four prediction
programs were >10%.
Genetic Risk Score Calculation
Genotyping of controls was performed on a HumanExome
Bead Chip (Illumina, San Diego, CA, USA) by the International
AMD Genomics consortium.30 Association testing and genetic
risk score (GRS) calculations were performed as described by
Grassmann et al.31 In brief, logistic regression analysis was
used to assess the association of common alleles (MAF > 0.01)
present in the coding regions of the ABCA4 gene. Since
variants rs1800717 and rs6666652 are highly correlated
(pairwise r2¼ 1, based on the EUR panel in the 1000 Genomes
Project, Build 20130502, http://www.internationalgenome.
org/; in the public domain), only rs6666652 was used in the
analysis. Variants with a MAF  0.01 and rare deep intronic
variants were not included in further calculations. Initially, we
determined the odds ratios (OR), 95% confidence intervals
(95% CI), and P values for each common variant. We adjusted
the resulting P values according to the false discovery rate
(FDR)32 and considered variants with an FDR < 0.05 to be
statistically significant. A GRS was calculated from significantly
associated variants for all controls and patients from a
multivariate logistic regression model. This was done by
multiplying the number of risk-modulating alleles (which can
be either 0, 1, or 2) with the respective logarithmic odds ratio
(log odds, computed from the multivariate model); then the
sum of all weighted genotypes was calculated. Finally, a
constant (1.0503) was subtracted from the score to center the
risk score distribution of the controls on zero.
Minigene Assay
Functional consequences of putative splicing variants were
analyzed with the pSPL3-based exon trapping system.33 Exons
harboring spliceogenic variants and control exons were PCR
amplified from genomic DNA using a 7:1 ratio of Taq:Pfu
polymerase and oligonucleotide primer pairs flanked by
restriction sites for EcoRI and BamHI (Supplementary Table
S1). The amplified products were cloned into the pSPL3b
vector. HEK293 cells were transfected in duplicate with 3 lg
construct DNA using TransIT-LT1 Transfection Reagent (Mirus
Bio, Madison, WI, USA) and harvested after 48 hours; total RNA
was extracted using RNeasy Micro Kit (Qiagen). Reverse
transcription–PCR was performed with the RevertAidH First
Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham,
MA, USA) and a pSPL3-specific SD6 (50-TCT GAG TCA CCT
GGA CAA CC-30) and SA4 (50-CAC CTG AGG AGT GAA TTG
GTC G-30) primer pair in combination with oligonucleotide
primers for the housekeeping genes ACTB (forward 50-GAC
ATC CGC AAA GAC CTG TA-30; reverse (50-CAG GAG AGC AAT
GAT CTT GA-30) and GUSB (forward 50-GAT CCA CCT CTG
ATG TTC AC-30; reverse (50-TAT TCC CCA GCA CTC TCG TC-
30). Polymerase chain reaction products were separated by
electrophoresis on a 2% agarose gel, excised, cloned, and
sequenced. Fragment analysis was done by PCR amplification
with fluorescein amidite (FAM)–labeled SD6 using Phusion
Flash High-Fidelity PCR Master Mix (Thermo Fisher Scientific).
Samples and a LIZ Size Standard (Applied Biosystems,
Darmstadt, Germany) were run on an ABI 3130xl sequencer
and analyzed with the Peak Scanner software (Applied
Biosystems).
RESULTS
Identification of ABCA4 Mutations
Mutational analysis of the ABCA4 gene was performed in 335
STGD1 patients and identified 189 unique sequence variations,
of which 171 were listed in the non-Finnish European ExAC
cohort as a rare variant with MAF  0.005. Of the 171 rare
ABCA4 variants, 148 were classified as pathogenic or likely
pathogenic and 23 as vus (Supplementary Table S2). Twenty-
eight percent (48/171) of the rare alleles constitute novel as yet
unpublished variants (Table 1). Missense mutations represent
59.6% (102/171) followed by nonsense and frameshift muta-
tions (15.8%; 27/171), splice site mutations (13.5%; 23/171)
and synonymous variants (8.8%; 15/171). Of note, variant
c.2588G>C is present with a MAF > 0.005 (0.0063; ExAC) but
was classified as pathogenic based on its known deleterious
effect on ABCA4 protein function.9,34,35
The most common pathogenic or likely pathogenic
mutations in our cohort were c.5882G>A (51 of 396 mutant
alleles), c.[3113C>T(;)1622T>C] (36/396), c.2588G>C (28/
396), and c.5461-10T>C (23/396), which is consistent with
our earlier report of frequent mutations in 144 German STGD1
patients.12 Together, these sequence changes account for
34.8% (138/396) of disease-associated variants. Ninety-nine
mutations were identified in only one patient (Supplementary
Table S2).
Impact of Selected ABCA4 Sequence Variants on
RNA Splicing Efficiency
Twenty-eight sequence variants were considered to have a
potential impact on splicing of the mature ABCA4 transcript
based on results from the bioinformatic analysis (Supplemen-
tary Table S2). Experimental evidence for splicing defects was
previously published for five of these (c.768G>T, c.2588G>C,
c.4253þ5G>A, c.5461-10T>C, c.5714þ5G>A) (Supplementary
Table S2). Here, functional pSPL3-based minigene assays were
performed for another 22 variants (Table 2; Supplementary Fig.
S1). The analysis of cDNAs derived from transfected HEK293
cells revealed aberrant pre-mRNA splicing for all of the 13
variants affecting canonical GT-AG splice sequences and for
c.4773þ3A>G located in the conserved donor splice site of
ABCA4 exon 33. This includes three mutations changing the
canonical GT to the weaker GC 50 splice site, which is present
in ~1% of authentic introns.36 The absence of functional donor
or acceptor splice sites led to exon skipping, intron retention,
and use of cryptic splice sites (Table 2; Supplementary Fig. S1),
likely leading to truncated protein products or nonsense-
mediated mRNA decay (NMD).
Of the eight exonic sequence changes included in the
minigene assay, three stop mutations and four missense
mutations were predicted to create cryptic canonical splice
sites, whereas the synonymous mutation c.3813G>A could
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weaken the donor splice site of exon 25 (Table 2). Four exonic
variants revealed both correct and aberrant splice products in
various proportions. Synonymous mutation c.3813G>A and
missense mutations c.4469G>A, c.4919G>A, and c.6647C>T
led to incorrectly spliced transcripts that match the predictions
from the bioinformatic analysis (Table 2; Supplementary Fig.
S1). Hence, these four variants initially classified as likely
pathogenic or vus were reclassified as being pathogenic
(Supplementary Table S2). Sequence variants c.122G>A/
p.(W41*), c.179C>T/p.(A60V), c.3808G>T/p.(E1270*), and
c.5189G>A/p.(W1730*) revealed no effect on mRNA splicing
in the in vitro assay.
Disease-Associated ABCA4 Alleles in 335 STGD
Patients
Two or more likely pathogenic or pathogenic changes in the
ABCA4 gene were found in 151 of the 335 STGD1 patients.
In another seven patients a deleterious mutation was
detected in addition to a vus, eventually raising the overall
detection rate of two expected mutations to 47.2%
(Supplementary Table S3). This includes 14 cases with null
mutations: c.[2692G>T(;)5461-10T>C(;)5606C>T],
c.[5018þ2T>C(;)6386þ2C>G], c.[296dupA];[5018þ2T>C],
c.[3813G>A(;)3813G>A], c.[4234C>T(;)5714þ5G>A],
TABLE 1. Novel Rare Sequence Variants in the ABCA4 Gene
Position on Chr. 1, hg19 Exon
Variant,
NM_000350.2 Protein Classification
94578624 2 c.67-2A>G p.(?) p
94578623 2 c.67-1G>C p.(I23Afs*24) p
94578603 2 c.86T>G p.(L29R) lp
94577116 3 c.180G>C p.(A60A) vus
94577090 3 c.206G>A p.(W69*) p
94574258 4 c.317A>T p.(Y106F) vus
94546177 8 c.956T>G p.(L319R) vus
94546124 8 c.1009T>C p.(F337L) vus
94543445 11 c.1357-2A>G p.(D453Gfs*14) p
94528844 12 c.1584C>A p.(Y528*) p
94528814 12 c.1614C>T p.(A538A) vus
94528736 12 c.1692A>G p.(P564P) vus
94528709 12 c.1719G>A p.(M573I) lp
94528277 13 c.1793T>G p.(V598G) vus
94528179 13 c.1891G>A p.(G631R) lp
94528152 13 c.1918C>G p.(P640A) lp
94517233 17 c.2609C>T p.(P870L) lp
94510310 20 c.2919-10T>C p.(?) vus
94510279 20 c.2940G>C p.(L980F) vus
94508989 21 c.3093delA p.(G1032Efs*52) p
94502701 25 c.3813G>A p.[(?, p.G1203Dfs*10)] p
94502343 26 c.3815T>C p.(I1272T) lp
94497591 27 c.3871C>T p.(Q1291*) p
94497562 27 c.3900A>G p.(R1300R) vus
94496083 29 c.4254-1G>C p.(?) p
94495989 29 c.4347G>T p.(W1449C) lp
94495186 30 c.4354G>T p.(E1452*) p
94488974 32 c.4635C>T p.(S1545S) vus
94488969 32 c.4640delA p.(K1547Rfs*34) p
94486835 35 c.4979C>T p.(P1660L) lp
94485197 36 c.5137C>A p.(Q1713K) lp
94485181 36 c.5153T>G p.(V1718G) lp
94485145 36 c.5189G>A p.(W1730*) p
94480196 38 c.5363C>T p.(P1788L) lp
94476924 39 c.5478C>T p.(N1826N) vus
94476889 39 c.5513A>G p.(H1838R) lp
94476844 39 c.5558C>A p.(A1853D) lp
94476464 40 c.5606C>T p.(P1869L) lp
94476414 40 c.5656G>A p.(G1886R) lp
94476352 40 c.5714þ4C>T p.(?) vus
94474314 41 c.5828T>C p.(L1943P) lp
94473286 43 c.5909T>C p.(L1970P) lp
94473253 43 c.5942C>G p.(T1981R) lp
94473222 43 c.5973G>C p.(V1991V) vus
94471067 44 c.6077T>C p.(L2026P) lp
94466664_94466663 46 c.6283-3_6283-2delinsAG p.(D2095Gfs*2) p
94466618 46 c.6326T>C p.(L2109P) lp
94463433 48 c.6713A>G p.(Q2238R) lp
lp, likely pathogenic; p, pathogenic.
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c.[4773þ3A>G(;)5461-10T>C], c.[5461-10T>C];[5461-10T>C],
c.[67-1G>C];[67-1G>C], c.[1A>G; 6089G>A];[5714þ5G>A],
c.[5714þ5G>A(;)5714þ5G>A], c.[5917delG];[5917delG], and
c.[5714þ5G>A];[5917delG]. The latter two combinations
were found in two patients (ID 86 and ID 255), and an
additional 58 cases were carrying a null and a missense
mutation (Supplementary Table S3). Compound heterozy-
gosity or homozygosity could be confirmed by segregation
analysis in 27 patients. One pathogenic or likely pathogenic
mutation was identified in 82 individuals, one vus in 13
cases resulting in a detection rate of 28.4% for carriers of a
single ABCA4 mutation (Supplementary Table S3). Complex
alleles verified by testing the parent(s) of the respective patients
were c.[1A>G; 6089G>A] in patient 219, c.[1609C>T;
5881G>A] in patient 314, c.[1622T>C; 3113C>T] in patients
1, 13, 106, 124, 273, 282, and 311, c.[2588G>C; 3289A>T]
in patient 75, and c.[2588G>C; 5153T>G] and c.[5318C>T;
6148G>C] together in patient 69. In a total of 89 patients
(26.6%) no disease-associated variant was found in the
ABCA4 gene.
Frequency of Deep Intronic Variants in Putative
Alternative Exons of the ABCA4 Gene
To investigate the frequency of deep intronic variants in the
ABCA4 locus in our patient cohort, we sequenced genomic
regions encompassing putative alternative exons in intron 30
and 36, namely, exon 30.1, exon 36.01, and exon 36.1. These
regions were previously identified by RNA sequencing of
retinal tissue (Supplementary Fig. S2).24,37,38 Ten different
sequence variants were found in 236 patients, of which four
(c.4539þ2028C>T, c.4540-2036C>A, c.5196þ1013A>G,
c.5196þ1056A>G) were defined as rare variants with a MAF
 0.005 in the 1000 Genomes catalog, phase 3 (Table 3;
Supplementary Fig. S2). These changes were each identified
once in the 472 alleles analyzed. Among these,
c.4539þ2028C>T and c.5196þ1056A>G have been described
previously by Braun et al. (2013)24 as V5 and V3, respectively,
and were later also found in another cohort of STGD1
patients.20 Deep intronic variants c.4540-2036C>A and
c.5196þ1013A>G are reported for the first time. The
c.5196þ1056A>G (V3) variant is predicted to strengthen a
cryptic donor splice site. Reverse transcriptase–PCR analysis
using keratinocyte mRNA of patients carrying the V3 variant
revealed the inclusion of a 177-bp segment into the ABCA4
transcript (termed ‘‘alternative exon 36.01’’), thus providing
experimental evidence for a loss-of-function effect of this
variation.24 Patient 230 in our cohort carried the V3 variant and
a second variant (c.2588G>C) annotated as pathogenic. This
suggests that the V3 mutation is indeed the second disease-
associated allele in our patient. A novel sequence change,
c.5196þ1013A>G, was found in patient 79 in combination
with c.1654G>A, a likely pathogenic missense mutation
[p.(V552I)]. Similar to the V3 variant, c.5196þ1013A>G is
predicted to strengthen a cryptic donor splice site and thus
may also result in deleterious effects upon splicing. Based on
bioinformatics, variants c.4539þ2028C>T (V5) and c.4540-
2036C>A are not predicted to affect splicing. The
c.4539þ2028C>T (V5) sequence change was identified in
patient 42 with no other probable mutant ABCA4 allele;
variant c.4540-2036C>A was detected in patient 159 in
addition to pathogenic mutation c.[1622T>C(;)3113C>T]
and likely pathogenic mutation c.3261A>C. A disease associ-
TABLE 2. Functional Analysis of Putative Splice Mutations in the ABCA4 Gene
Exon Variant, NM_000350.2 Predicted Effect* Protein Major Missplicing†
Predicted Protein of Major
Misspliced Transcript
Variants in canonical and conserved splice sites
2 c.67-1G>C Loss of AS NA Skipping of exon 2 p.(I23Afs*24)
2 c.160þ2T>C Loss of DS NA Retention of intron 2 p.(?)
9 c.1239þ1G>C Loss of DS NA Skipping of exon 9 p.(T367Sfs*6)
11 c.1357-2A>G Loss of AS, Cryptic AS NA Cryptic AS in intron 10 p.(D453Gfs*14)
13 c.1937þ1G>A Loss of DS NA Cryptic DS in exon 13
and intron 13
p.[(Y603_S646del, F647*)]
14 c.2160þ1G>T Loss of DS NA Retention of intron 14 p.(?)
29 c.4352þ1G>A Loss of DS NA Skipping of exon 29 p.(S1418_P1451delinsR)
33 c.4773þ3A>G Weakens DS NA Skipping of exon 33 and 34 p.(Y1557Cfs*45)
35 c.5018þ2T>C Loss of DS NA Retention of intron 35,
skipping of exon 35
p.[(?, V1617Afs*113)]
36 c.5196þ1G>A Loss of DS NA Retention of intron 36 p.(?)
36 c.5196þ2T>C Loss of DS NA Retention of intron 36 p.(?)
37 c.5312þ1G>A Loss of DS NA Skipping of exon 37 p.(N1734Gfs*14)
46 c.6283-3_6283-2delinsAG Loss of AS, Cryptic AS NA Cryptic AS in intron 45 p.(D2095Gfs*2)
46 c.6386þ2C>G Loss of DS NA Cryptic DS in exon 46 p.(V2114Hfs*5)
Exonic variants
2 c.122G>A Cryptic AS p.(W41*) None –
3 c.179C>T Cryptic DS p.(A60V) None –
25 c.3808G>T Cryptic DS p.(E1270*) None –
25 c.3813G>A Weakens DS p.(E1271E) Retention of intron 25 p.(?)
30 c.4469G>A Cryptic DS p.(C1490Y) Cryptic DS in exon 30 p.(C1490Efs*12)
35 c.4919G>A Cryptic AS p.(R1640Q) Cryptic AS in exon 35 p.(V1617_R1640del)
36 c.5189G>A Cryptic AS p.(W1730*) None –
48 c.6647C>T Cryptic DS p.(A2216V) Cryptic DS in exon 48 p.(A2216_Q2243del)
AS, conserved acceptor site; DS, conserved donor site.
* Alamut Software: SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing Finder.
† Misspliced transcripts found in control and mutant constructs are not listed.
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ation of these intronic variants in our patients is thus unclear.
Six previously reported intronic sequence changes
(c.4539þ2001G>A, c.4539þ2064C>T, c.5196þ1136C>A,
c.5196þ1137G>A, c.5196þ1159G>A, c.5196þ1216C>A) were
not found in our patient cohort (Table 3).
The Contribution of Common ABCA4 Variants to
STGD1
We noticed a striking difference in the frequencies of common
ABCA4 variants (MAF ‡ 0.01) in the patient versus the control
group (Supplementary Table S2; Fig. 1). This led us to
investigate whether such variants may exert an effect on the
risk for developing STGD1. Genotype information on 16
common ABCA4 variants was available for the 335 patients
and 781 German controls from Lower Franconia. For each
variant, risk association was computed applying a logistic
regression model. We found statistically significant association
for six variations (c.1268A>G, c.4203C>A, c.5603A>T,
c.5682G>C, c.5843C>T, c.6249C>T) (FDR < 0.05, Supple-
mentary Table S4). To estimate the independence of the
associated variants, we fit a multivariate logistic regression
model incorporating these variations. In the multivariate
model, association of variant c.4203C>A (rs1801666) with
disease risk was no longer statistically significant, probably due
to linkage disequilibrium with the strongly associated variant
c.5603A>T (rs1801466, r2 ¼ 0.38). The remaining five risk-
modulating variants were found to be independently associated
with disease risk (Table 4). Repeating the analysis excluding
the data from 52 samples of non-European or unknown
ancestry, similar results were obtained, including the signifi-
cant and independent association of the five risk-modulating
variants (c.1268A>G, c.5603A>T, c.5682G>C, c.5843C>T,
c.6249C>T) with similar effect sizes.
Assuming that common pathogenic mutations emerged on
common haplotypes tagged by associated variants, our analysis
may measure their impact on disease risk rather than that of
the common associated variant. We therefore evaluated the
correlation between common mutations in our cohort
(c.1622T>C, c.2588G>C, c.3113C>T, c.4234C>T, c.5461-
10T>C, c.5714þ5G>A, c.5882G>A, c.5917delG) and the five
risk-modulating variants (c.1268A>G, c.5603A>T, c.5682G>C,
c.5843C>T, c.6249C>T). Three frequent mutations
(c.2588G>C, c.5461-10T>C, c.5882G>A) were found to be
potentially correlated (R2 > 0.05) with common STGD1-
associated variants. Subsequently, the association analysis was
repeated by excluding individuals carrying any of three
correlated pathogenic mutations c.5882G>A, c.2588G>C,
and c.5461-10T>C from the analysis. Still, STGD1 association
of common variants c.1268A>G and c.5603A>T remained
highly significant (P values of 3.45E-05 and 4.82E-05, respec-
TABLE 3. Deep Intronic Variants in the ABCA4 Gene
Position on Chr. 1, hg19 Variant, NM_000350.2 Predicted Effect*
MAF, 236 STGD1
Patients
MAF,
Controls† Reference
Exon 30.1
94493231 c.4539þ1770C>A – 0.055 0.061 –
94493000 c.4539þ2001G>A – 0 – 20, 24–26
94492973 c.4539þ2028C>T – 0.002 – 20, 24
94492937 c.[4539þ2064C>T; 5461-1389C>A] – 0 – 20
94492773 c.4540-2169A>G – 0.432 0.431 –
94492681 c.4540-2077C>T – 0.002 0.008 –
94492640 c.4540-2036C>A – 0.002 – –
Exon 36.01/36.1
94484239 c.5196þ899C>T – 0.032 0.023 –
94484125 c.5196þ1013A>G Strengthens cryptic DS 0.002 – –
94484123 c.5196þ1015A>G – 0.053 0.058 –
94484082 c.5196þ1056A>G Strengthens cryptic DS 0.002 – 20, 24
94484060 c.5196þ1078delA – 0.021 0.023 –
94484002 c.5196þ1136C>A Novel cryptic AS 0 0 25
94484001 c.5196þ1137G>A Strengthens cryptic AS 0 – 20, 21, 24–26
94483979 c.5196þ1159G>A Novel cryptic AS 0 0.002 25
94483922 c.5196þ1216C>A Strengthens cryptic DS 0 – 24
AS, conserved acceptor site; DS, conserved donor site.
* Alamut Visual 2.7.1.
† 1000 Genomes Project.
FIGURE 1. Frequency of common ABCA4 variants in patients with
Stargardt disease and European non-Finnish controls. Six variants that
were found to be significantly enriched in either patients or controls
are framed.
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tively). Similarly, removing patients carrying one of the eight
most common STGD1 mutations (c.5882G>A, c.3113C>T,
c.1622T>C, c.2588G>C, c.5461-10T>C, c.5714þ5G>A,
c.4234C>T, or c.5917delG) from the analysis resulted in a
statistically significant association for the common variants
c.5603A>T and c.1268A>G (P values of 0.000273 and 0.0109,
respectively) (Supplementary Table S5). For variant
c.6249C>T, the association was no longer significant after
removal of patients carrying common mutations, although the
variant still revealed a similar effect size. The latter finding
suggests that loss of significance is likely due to lack of
statistical power caused by the reduced number of individuals
in the subsequent analyses (from n¼335 to n¼247 to n¼197
patients, Supplementary Table S5). In contrast, variant
c.5682G>C showed a reduced effect size and also a lack of
statistically significant association in both subsequent analyses.
To further evaluate the role of these common variants in
retinal pathology, a GRS was calculated for the STGD1 patients
in our cohort and the 781 control individuals. This was
computed as the sum of risk-increasing and protective alleles
weighted by the relative effect size of each of the risk-
modulating variants from the multivariate logistic regression
model. An alpha estimate of 1.0503 was used to center the
GRS on zero for the controls. Patients diagnosed with STGD1
have a significantly higher mean GRS (0.418; P value < 1016,
95% CI: 0.3479–0.4887) compared to controls (0.0, 95% CI:
0.0466 to 0.0466) (Fig. 2). Importantly, patients with one,
two, or more disease-associated ABCA4 mutations have a
significantly higher GRS than those with none (P¼ 0.0011 and
0.0024; respectively) (Fig. 2), implying a risk-increasing effect
of common ABCA4 alleles when combined with a single
defective copy of the ABCA4 gene.
DISCUSSION
Almost 20 years after the identification of ABCA4 as the
causative gene for autosomal recessive STGD1,3 the genetics of
this common form of hereditary macular degeneration still
have not fully been clarified. Our study describes the findingsT
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FIGURE 2. Genetic risk score (GRS) for patients and controls stratified
according to the number of ABCA4 mutations or disease status. An
alpha estimate of1.0503 was used to center the GRS on zero for the
controls. Red bars represent the mean GRS and confidence intervals.
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of mutational profiling of the ABCA4 gene in the largest cohort
of STGD1 patients published so far. A total of 171 unique rare
sequence variants, 48 of which constitute novel, so far
unreported, mutations, were identified in the coding region,
and an additional four rare deep intronic variants were
detected in intron 30 and 36 of the ABCA4 gene. In 47% of
patients, two causative ABCA4 mutations were found. This is at
the lower end of the mutation detection rate in STGD1
patients, with other studies identifying biallelic mutations
between 55% and 80%,17,19,21,39,40 but may be explained by a
combination of factors. First, clinical heterogeneity and
variable diagnostic criteria inherent to multiclinic retrospective
cohort studies may have led to uncertainties in clinical
diagnosis in some patients of our cohort. In addition, small
deletions/insertions may have been missed due to limitations in
the detection accuracy of this type of mutation by the
resequencing array and ION Torrent semiconductor technol-
ogy. Finally, large rearrangements within the ABCA4 locus that
have been shown to occur in 0.3% to 2.2% of the analyzed
chromosomes in previous reports9,26,41 would not have been
detected by the mutational screening in this study.
An important question relates to the high proportion of
carriers of single ABCA4 mutations consistently observed in
numerous studies regardless of the ethnic background of the
patients.14,15,18,19,21,39,40,42 A single mutant ABCA4 allele was
found in almost 30% of the 335 individuals in our patient
group, a number representing the upper end of the reported
ranges. Mutations in noncoding regions of the ABCA4 gene
locus have been proposed as a common source for a second
causative mutation. More specifically, several studies have
described the occurrence of deep intronic variants in intron 30
and 36 in a significant proportion of patients (7.9–17.9%) with
single ABCA4 mutations.20,21,24–26 Indeed, there is some
experimental evidence that a few of these variants activate/
strengthen cryptic splice sites leading to the inclusion of
alternative exons in the mature transcript.24 In our cohort, of
95 STGD patients with a single pathogenic/likely pathogenic
ABCA4 mutation, only 2 were found to carry an additional rare
intronic variant in intron 30 or 36 (2.1%). Two other novel rare
intronic variants were detected in a patient with two causative
ABCA4 mutations and a patient with no ABCA4 mutations,
respectively. From these data, we conclude that causative
ABCA4 mutations in intron 30 and 36 may contribute to
STGD1 pathogenesis only in a minority of cases. Similarly, in a
small German cohort of 46 patients with single heterozygous
ABCA4 variants, no mutations were found in these intronic
regions.25
To further add to the discussion on the impact of deep
intronic variants to STGD1 disease, the full sequence analysis of
the entire ABCA4 locus including exonic as well as intronic
sequences will be needed independent of the patient’s
mutation status. It was estimated that approximately 95% of
multiexon transcripts undergo alternative splicing.43 While the
key components and mechanisms involved in mRNA process-
ing are reasonably well understood, high-confidence predic-
tions on splicing effects of defined sequence changes remain
inaccurate. In this context, it is of note that the extent and
variability of alternative splicing in the human retina were
found to be remarkable,37 although the functional consequenc-
es of the alternative transcripts remain obscure. Approximately
13% of novel mRNA junctions were expressed in the retina at
levels similar to or higher than the reference transcript. Deep
RNA sequencing of three healthy human retinas revealed at
least 11 alternatively spliced exons and 71 alternative exon/
intron junctions,37 implying the possibility of additional deep
intronic regions as candidates to potentially harbor mutations
affecting the correct splicing of the ABCA4 transcript.
Considering that 7.6% of STGD1 patients of a Belgian cohort
carried a founder deep intronic c.4539þ2001G>A mutation,25
it is conceivable that a significant fraction of the German STGD1
patients carry as yet unknown mutations in the noncoding
regions of the ABCA4 gene.
To address the strikingly high frequency of carriers with
only a single identified ABCA4 disease allele, we assessed the
contribution of common ABCA4 variants on disease develop-
ment. To this end, our findings reveal that variants c.1268A>G
(OR 0.6682; CI 0.531–0.836), c.5843C>T (OR 0.1678; 0.063–
0.377), and c.6249C>T (OR 0.6483; CI 0.407–1.001) exert a
protective effect, while variants c.5603A>T (OR 1.9652; CI
1.335–2.909) and c.5682G>C (OR 1.3973; CI 1.082–1.800)
confer an increased risk for developing STGD1. These results
are in agreement with and extend previous studies that
identified c.5603A>T as a risk-increasing allele44 and
c.1268A>G as a protective variant.40 Our data now facilitate
a GRS estimate that coalesces the total effect of protective and
risk-increasing alleles similarly to the model developed to
assess the genetic risk for AMD.31 Interestingly, the GRS in the
group of patients with only a single disease-associated ABCA4
mutation is significantly higher than in patients with no ABCA4
mutation, suggesting that common variants are involved in
conferring risk for STGD1.
Simultaneous loss of significant association with STGD1 and
effect size was observed for common variant c.5682G>C when
the three most frequent pathogenic mutations were excluded
from the analysis. This could be due to linkage disequilibrium
between certain pathogenic mutations and c.5682G>C,
implying that the common ABCA4 allele either has no effect
on the pathogenicity of the rare variant or adds to the
damaging effect of the mutation. Furthermore, c.5682G>C
may act as a risk-increasing allele only in trans when combined
with specific pathogenic mutations. The assumption that the
presence of a common genetic variant with an adverse effect
on ABCA4 function actually triggers the deleterious conse-
quences of the pathogenic mutation could explain why some
of the common mutations have a frequency of >1% in certain
populations but do probably not cause STGD1 in the
respective carriers. For example, the allele frequency of
pathogenic mutation c.5882G>A/p.(G1961E) is 1.4% in the
South Asian population (ExAC) and even higher in Somalia,45
although a higher prevalence of STGD1 in these countries has
not been reported. Alternatively, a protective ABCA4 allele may
ameliorate a pathogenic mutation in trans, although only in
combination with a less severe ABCA4 allele. In this context, it
should be noted that protective variant c.6249C>T is five times
more frequent in the African than in the European or Asian
populations.
The GRS model may also explain another discrepant aspect
in our patient cohort. Fourteen STGD1 patients in our study
each harbor two null mutations in the ABCA4 gene.
Compound heterozygosity/homozygosity could be confirmed
in seven of these patients. In accordance with the hypothesis
by Maugeri et al.,9 the presence of the severe mutations in our
patients would strongly suggest a cone–rod dystrophy or an
atypical retinitis pigmentosa phenotype, thus reflecting the
greatly reduced or even absent functional activity of ABCA4. A
review of the clinical data, however, verified that all 14 patients
presented with typical symptoms of STGD1 disease with age of
onset ranging between 4 and 60 years. More precisely, eight
patients presented with initial symptoms at the age of 11 or
younger; two patients were under 20; and the remaining four
patients were 30 to 60 years old when they first noticed vision
problems. In another report, one-third of the nontruncating
ABCA4 alleles were found to cause more severe disease than
premature truncations.10 Thus, specific common ABCA4
variants may alleviate deleterious mutations leading to asymp-
tomatic, mild, or less severe disease and vice versa. Taken
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together, future studies aiming at investigation of the influence
of common variations and rare mutations on disease risk are
necessary, ideally in a prospective cohort setting.
In summary, despite certain shortcomings in terms of
possible uncertainties in clinical diagnosis and the paucity of
detecting large copy number variations (CNVs) or mutations in
noncoding regions, the present study further broadens our
knowledge about the genetic basis of STGD1 disease. First, we
expanded the mutational spectrum of STGD1 by identifying an
additional 48 novel pathogenic/likely pathogenic gene variants
in ABCA4. Our findings also add to the clarification of the role
of deep intronic variants in putative alternative exons within
intron 30 and 36, which seem to represent only a minor
proportion of disease-associated variants. Finally, an in-depth
analysis of common variants at the ABCA4 gene locus revealed
risk-altering properties for several common variants, particu-
larly in those patients who carry only a single disease-
associated ABCA4 allele. Furthermore, GRS data can be used
to ascertain the risk of a patient with a single ABCA4 mutation
and may further refine our understanding of ABCA4-associated
retinal pathology.
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